Browsing by Author "Anil K. Jaiswal"

Now showing 1 - 4 of 4

A prospective randomized comparison of simultaneous integrated boost with sequential boost intensity-modulated radiotherapy in locally advanced head and neck cancer
(Wolters Kluwer Medknow Publications, 2022) Nilesh Mani; Sushil K. Aggarwal; Ishan Kumar; Abhijit Mandal; Garima Jaiswal; Rakesh Ranjan; Anil K. Jaiswal; Neha Gupta; Ankita Singh; Ankur Mourya; Lalit M. Aggarwal; Sunil Choudhary
Purpose: A comparison of simultaneous integrated boost (SIB) with sequential boost (SEQ) using intensity-modulated radiotherapy along with concurrent cisplatin in locally advanced head and neck cancer (HNC) was made with regard to their survival outcomes and toxicity profile. Materials and Methods: A total of 34 patients were enrolled between October 2016 and March 2019. They were randomized into two arms, SIB and SEQB. All patients were treated with 6 MV photon beam on Linear Accelerator with weekly concurrent cisplatin at 35 mg/m 2. Overall survival (OS) and disease-free survival (DFS) were the primary end points and acute and late toxicities were the secondary end points. Results: The median follow-up period was 40.6 and 37.3 months for SIB and SEQB, respectively. At the end of 5 years, the median OS was 40.6 and 37.3 months (P = 0.947) and the median DFS was 35.1 and 37.3 months in the SIB and SEQB arms, respectively (P = 0.991).complete response at 3 months was 64.7% and 76.5% and partial response was 23.5% and 17.6%, whereas progressive disease was 11.8% and 5.9% in SIB and SEQB arms, respectively. Acute dermatitis, mucositis, dysphagia, and salivary gland toxicities were higher in the SIB arm compared to the SEQB arm. Conclusion: SIB and SEQ arms were comparable in terms of OS and DFS. However, the acute toxicities were higher in the SIB arm, although the difference was not significant, compared to the SEQB arm. © 2022 Wolters Kluwer Medknow Publications. All rights reserved.
Comparative analysis of cellular immune responses in treated Leishmania patients and hamsters against recombinant Th1 stimulatory proteins of Leishmania donovani
(Frontiers Media S.A., 2016) Sumit Joshi; Narendra K. Yadav; Keerti Rawat; Chandra Dev P. Tripathi; Anil K. Jaiswal; Prashant Khare; Rati Tandon; Rajendra K. Baharia; Sanchita Das; Reema Gupta; Pramod K. Kushawaha; Shyam Sundar; Amogh A. Sahasrabuddhe; Anuradha Dube
Our prior studies demonstrated that cellular response of T helper 1 (Th1) type was generated by a soluble antigenic fraction (ranging from 89.9 to 97.1 kDa) of Leishmania donovani promastigote, in treated Leishmania patients as well as hamsters and showed significant prophylactic potential against experimental visceral leishmaniasis (VL). Eighteen Th1 stimulatory proteins were identified through proteomic analysis of this subfraction, out of which 15 were developed as recombinant proteins. In the present work, we have evaluated these 15 recombinant proteins simultaneously for their comparative cellular responses in treated Leishmania patients and hamsters. Six proteins viz. elongation factor-2, enolase, aldolase, triose phosphate isomerase, protein disulfide isomerase, and p45 emerged as most immunogenic as they produced a significant lymphoproliferative response, nitric oxide generation and Th1 cytokine response in PBMCs and lymphocytes of treated Leishmania patients and hamsters respectively. The results suggested that these proteins may be exploited for developing a successful poly-protein and/or poly-epitope vaccine against VL. © 2016 Joshi, Yadav, Rawat, Tripathi, Jaiswal, Khare, Tandon, Baharia, Das, Gupta, Kushawaha, Sundar, Sahasrabuddhe and Dube.
Percutaneous high‑dose‑rate interstitial brachytherapy for non‑resectable, chemo resistant malignant lesion of lung and liver
(Wolters Kluwer Medknow Publications, 2023) Nandlal Yadawa; Uday P. Shahi; Abhijit Mandal; Ashish Verma; Kiran Kumari; Lalit M. Aggrawal; Isha Jaiswal; Ankur Mourya; Anil K. Jaiswal; Pammy Srivastava
Purpose: To explore the feasibility and efficacy of interstitial brachytherapy application for nonresectable and chemo‑resistant malignant liver and lung lesions. Materials and Methods: Percutaneous high‑dose‑rate interstitial brachytherapy (HDR ISBT) was applied in nine lesions of seven middle‑aged patients with advanced carcinoma (five patients with liver lesion and two patients with lung lesion). All patients were surgically ineligible. All patients had already received systemic chemotherapy. Under computed tomography (CT) guidance (for lung lesion) or ultrasonography (USG) guidance (for liver lesion), a single stainless steel brachytherapy needle was inserted percutaneously in patients with lesion size ≤4 centimeter (cm) and multiple needles were inserted in patients of lesion size >4cm. A single dose of 15 Gy to 20 Gy with HDR ISBT was prescribed at the periphery of the lesion. The needles were removed just after treatment. Patients were kept under observation for 24 h after treatment. Results: The median size of the lesion was 6.5 cm. In all the cases of liver lesion, more than 75% shrinkage of tumor volume in follow‑up at 6 mo was observed. It was more than 50% for lung lesion. None of the patients had developed significant complications as on the median follow up period of 15 mo (ranges 3–27 mo). Conclusions: Percutaneous CT‑guided high‑dose‑rate interstitial brachytherapy is a minimally invasive, safe, and feasible treatment option with minimal complication for inoperable, chemo resistant, advanced cancers with encouraging treatment outcomes. © 2023 Journal of Cancer Research and Therapeutics.
Transgenic Leishmania donovani clinical isolates expressing green fluorescent protein constitutively for rapid and reliable ex vivo drug screening
(2009) Nasib Singh; Reema Gupta; Anil K. Jaiswal; Shyam Sundar; Anuradha Dube
Objectives: Several Leishmania strains with episomal expression of green fluorescent protein (GFP) require constant drug pressure for its continuous expression and hence limit its use in ex vivo or in vivo systems. The aim of this study was to alleviate this problem by stably integrating the GFP gene into the parasite genome, so as to use these transfectants for ex vivo and in vivo drug screening. Methods: The GFP gene was integrated downstream of the 18S ribosomal promoter region of Leishmania donovani. After initial selection, GFP-expressing parasites - both sodium stibogluconate (SAG)-susceptible (2001) and -resistant (2039) isolates - were grown without adding G418. The infectivity of these transfectants to macrophages (J774.1) as well as to hamsters was checked. The ex vivo screening assay was standardized using standard antileishmanial drugs. Results: A constitutive and enhanced expression of GFP in promastigote and amastigote stages was achieved for ∼12 months without any need for drug pressure. These transfectants were highly infective to macrophage cell lines as well as to hamsters, as observed by fluorescence microscopy and flow cytometry (FACS). GFP-tagged promastigotes as well as intracellular amastigotes were found to be highly susceptible to miltefosine, amphotericin B and pentamidine, in a concentration-dependent manner. SAG was inactive against the GFP-promastigotes, as well as SAG-resistant intracellular amastigotes, correlating well with earlier reports. Conclusions: The GFP-transfectants were found to be suitable for FACS-based ex vivo screening assays. They were also infective to hamsters up to day 60 post-infection. © The Author 2009. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.